Citi raised the firm’s price target on Apogee Therapeutics (APGE) to $125 from $95 and keeps a Buy rating on the shares. The firm believes the Phase 2a data further supports the thesis that zumilokibart can “reset” the atopic dermatitis standard of care. The share setup into further data readouts remains favorable, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics price target raised to $130 from $89 at Canaccord
- Apogee Therapeutics: Strong Phase IIa IL‑13 Data Support Buy Rating and Long-Term Upside in Atopic Dermatitis
- APGE: Zumilokibart’s Best-in-Class Atopic Dermatitis Profile and Long-Acting Dosing Support Buy Rating and Re-Rating Potential
- Apogee Therapeutics announces $300M common stock offering
- Morning News Wrap-Up 3/23/26: Today’s Biggest Stock Market Stories!